Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.

Oncologist · 2021 · PMC7873327 · PMID 33215787

Europe PMC DOI

hedged sentence

0.2530

closest p · 5.1× alpha

0.2530

boldest claim

The sentences

showed a trendp = .253not close (p > 0.1)

In this subgroup, TMB showed a trend toward a positive but weak correlation ( r = 0.377; p = .253) with PFS on anti‐PD1 treatment (Fig. 2A ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.